Serum nitrotyrosine and psychometric tests as indicators of impaired fitness to drive in cirrhotic patients with minimal hepatic encephalopathy

Liver International

Volumn 33, Issue 10, 2013, Pages 1478-1489

  Felipo, Vicente ^a   Urios, Amparo ^b   Valero, Pedro ^c   Sánchez, Mar ^c   Serra, Miguel A ^b   Pareja, Ignacio ^c   Rodríguez, Felicidad ^b   Gimenez Garzó, Carla ^a   Sanmartín, Jaime ^c   Montoliu, Carmina ^b  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

3 nitrotyrosine; Fitness to drive; Minimal hepatic encephalopathy; Psychometric tests

Indexed keywords

3 NITROTYROSINE; AMMONIA; CYCLIC GMP; INTERLEUKIN 18; INTERLEUKIN 6;

AMMONIA BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DRIVING ABILITY; ENZYME METABOLISM; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PSYCHOMETRY; PSYCHOMOTOR DISORDER; REACTION TIME;

3-NITROTYROSINE; FITNESS TO DRIVE; MINIMAL HEPATIC ENCEPHALOPATHY; PSYCHOMETRIC TESTS;

ADULT; AGED; ANALYSIS OF VARIANCE; AUTOMOBILE DRIVING; BIOLOGICAL MARKERS; CHEMOKINES; CYCLIC GMP; FLICKER FUSION; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED; NITRIC OXIDE; PSYCHOMETRICS; TYROSINE;

EID: 84885182011     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12206     Document Type: Article

References (42)

1. Romero-Gómez M, Boza F, García-Valdecasas MS, García E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718-23.
2. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16: 531-5.
3. Häussinger D, Cordoba J, Kircheis G, et al. Definition and assessment of low-grade hepatic encephalopathy. In: Häussinger D, Kircheis G, Schliess F, eds. Hepatic Encephalopathy and Nitrogen Metabolism. Berlin Heidelberg, New York: Springer, 2006; 423-32.
4. Román E, Córdoba J, Torrens M, et al. Minimal hepatic encephalopathy is associated with falls. Am J Gastroenterol 2011; 106: 476-82.
5. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998; 28: 45-9.
6. Srivastava A, Mehta R, Rothke SP, Rademaker AW, Blei AT. Fitness to drive in patients with cirrhosis and portal-systemic shunting: a pilot study evaluating driving performance. J Hepatol 1994; 21: 1023-8.
7. Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39: 739-45.
8. Kircheis G, Knoche A, Hilger N, et al. Hepatic encephalopathy and fitness to drive. Gastroenterology 2009; 137: 1706-15.
9. Watanabe A, Tuchida T, Yata Y, Kuwabara Y. Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metab Brain Dis 1995; 10: 239-48.
10. Bajaj JS, Hafeezullah M, Hoffmann RG, et al. Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology 2008; 47: 596-604.
11. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009; 50: 1175-83.
12. Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007; 102: 1903-9.
13. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012; 55: 1164-71.
14. Weissenborn K, Giewekemeyer K, Heidenreich S, et al. Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis 2005; 20: 359-67.
15. Amodio P, Schiff S, Del Piccolo F, et al. Attention dysfunction in cirrhotic patients: an inquiry on the role of executive control, attention orienting and focusing. Metab Brain Dis 2005; 20: 115-27.
16. Felipo V, Ordoño JF, Urios A, et al. Patients with minimal hepatic encephalopathy show impaired mismatch negativity correlating with reduced performance in attention tests. Hepatology 2012; 55: 530-9.
17. Weissenborn K, Ennen JC, Schomerus H, Rückert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34: 768-73.
18. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40: 247-54.
19. Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007; 22: 125-38.
20. Felipo V, Urios A, Montesinos E, et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis 2012; 27: 51-8.
21. Rodrigo R, Cauli O, Gomez-Pinedo U, et al. Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy. Gastroenterology 2010; 139: 675-84.
22. Montoliu C, Piedrafita B, Serra MA, et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J Clin Gastroenterol 2009; 43: 272-9.
23. Montoliu C, Piedrafita B, Serra MA, et al. Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients. J Mol Med 2007; 85: 237-45.
24. Montoliu C, Cauli O, Urios A, et al. 3-nitrotyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Am J Gastroenterol 2011; 106: 1629-37.
25. World Medical Organization. Declaration of Helsinki. BMJ 1996; 313: 1448-9.
26. Montoliu C, Kosenko E, Del Olmo JA, et al. Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis. Liver Int 2005; 25: 787-95.
27. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
28. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Häussinger D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002; 35: 357-66.
29. Romero-Gómez M, Córdoba J, Jover R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007; 45: 879-85.
30. Bajaj JS, Heuman DM, Wade JB, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478-87.
31. Coma I, Rueda S, Sánchez M, Fernández M. Diseño interactivo de escenarios para simulación de conducción. Revista de Enseñanza y Tecnología 2002; 22: 5-12.
32. Van Winsum W, Brookhuis KA, de Waard D. A comparison of different ways to approximate time-to-line crossing (TLC) during car driving. Accid Anal Prev 2000; 32: 47-56.
33. Wolf Y, Algom DY, Lewin I. A signal detection theory analysis of a driving decision task: spatial gap acceptance. Percept Mot Skills 1988; 66: 683-702.
34. Hoffman L, McDowd JM. Simulator driving performance predicts accident reports five years later. Psychol Aging 2010; 25: 741-5.
35. Mayhew DR, Simpson HM, Wood KM, et al. On-road and simulated driving: concurrent and discriminant validation. J Safety Res 2011; 42: 267-75.
36. Jamson S, Lai F, Jamson H. Driving simulators for robust comparisons: a case study evaluating road safety engineering treatments. Accid Anal Prev 2010; 42: 961-71.
37. Törnros J. Driving behavior in a real and a simulated road tunnel-a validation study. Accid Anal Prev 1998; 30: 497-503.
38. Curran S, Wattis J. Critical flicker fusion threshold: a potentially useful measure for the early detection of Alzheimer's disease. Hum Psychopharmacol 2000; 15: 103-12.
39. Anstey KJ, Wood J, Lord S, et al. Cognitive, sensory and physical factors enabling driving safety in older adults. Clin Psychol Rev 2005; 25: 45-65.
40. Kim Y, Park G, Lee M, Lee JH. Impairment of driving ability and neuropsychological function in patients with MHE disease. Cyberpsychol Behav 2009; 12: 433-6.
41. Bajaj JS, Hafeezullah M, Zadvornova Y, et al. The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol 2009; 104: 898-905.
42. Darwish RS, Amiridze N, Aarabi B. Nitrotyrosine as an oxidative stress marker: evidence for involvement in neurologic outcome in human traumatic brain injury. J Trauma 2007; 63: 439-42.